Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 02.11.2026 1 AJR Am J Roentgenol 1 Am J Clin Oncol 2 Am J Respir Crit Care Med 2 Ann Oncol 3 Ann Thorac Surg 5 Anticancer Res 8 BMC Cancer 2 Cancer Lett 1 Clin Cancer Res 1 Eur Respir J 1 J Cancer Res Clin Oncol 3 J Clin Oncol 1 J Natl Cancer Inst 3 J Thorac Cardiovasc Surg 2 J Thorac Oncol 1 JAMA Oncol 3 Lancet 4 Lung Cancer 3 N Engl J Med 1 Nat Med 2 Oncogene

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. ROSENKRANTZ AB
   October 2026: Lung Cancer Habitat Imaging, Axillary Lymphadenopathy, Prostate Feeding Artery, and More.
   AJR Am J Roentgenol. 2026 Oct 28:1-2. doi: 10.2214/AJR.26.35062.
   PubMed        
   
   

   
   Am J Clin Oncol

2. KANAN T, Kanan D, Kandula M
   Discovery of Promising USP21 Small Molecule Inhibitors: A Computational and Artificial Intelligence Modeling-Based Drug Repurposing Study for Non-Small Cell Lung Cancer.
   Am J Clin Oncol. 2026 Oct 30. doi: 10.1097/COC.0000000000001391.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

3. ZHOU E, Zeng J, Liu C, Li P, et al
   Preoperative short-term PM2.5 Exposure and Postoperative Pulmonary Complications After Lung Cancer Surgery.
   Am J Respir Crit Care Med. 2026 Oct 26:aamag575. doi: 10.1093.
   PubMed        
   
   
4. NANDIGAMA R, Cheikh BB, Wilhelm J, Nikulina N, et al
   Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in non-small cell lung cancer.
   Am J Respir Crit Care Med. 2026;212:2778-2791.
   PubMed         Abstract available
   
   

   
   Ann Oncol

5. LI ZM, Wu L, Wang WX, Sun LH, et al
   Final Analysis of the Neotorch Study: Perioperative Toripalimab in Combination with Chemotherapy for Patients with Stage ?/? Resectable Non-Small Cell Lung Cancer.
   Ann Oncol. 2026 Dec 31:S0923-7534(26)06875-4. doi: 10.1016/j.annonc.2026.
   PubMed         Abstract available
   
   
6. RUDIN CM, Ahn MJ, Schuler M, Blackhall FH, et al
   Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study.
   Ann Oncol. 2026 Oct 26:S0923-7534(26)06876-6. doi: 10.1016/j.annonc.2026.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

7. GUORGUI J, Hutson J, Kamtam D, Kim JJ, et al
   Impact of High SUVmax on Recurrence by Resection Strategy in Stage IA Adenocarcinoma
   Ann Thorac Surg. 2026;122:1327-1335.
   PubMed         Abstract available
   
   
8. MORI S, Li L, Arakawa S, Tsubouchi S, et al
   Clinical Feasibility of Robot-Assisted Pulmonary Resection Using a Platform Incorporating Haptic Feedback.
   Ann Thorac Surg. 2026 Jun 27:S0003-4975(26)00675.
   PubMed         Abstract available
   
   
9. SUZUKI Y, Sarkaria IS, Ha E, Christie IG, et al
   Feasibility and Outcomes of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion for Pleural Mesothelioma.
   Ann Thorac Surg. 2026;122:1347-1355.
   PubMed         Abstract available
   
   

   
   Anticancer Res

10. ISHIDA Y, Yuasa R, Nakamuta K, Wada T, et al
    Abscopal-like Regression of Lung Metastases After Near-infrared Photoimmunotherapy Plus Nivolumab in Laryngeal Carcinoma.
    Anticancer Res. 2026;46:6457-6465.
    PubMed         Abstract available
    
    
11. TSUKAMOTO YO, Nakada T, Kuroda N, Tsubouchi S, et al
    Field Cancerization and Recurrence Patterns After Resection of Pulmonary Squamous Cell Carcinoma.
    Anticancer Res. 2026;46:6409-6416.
    PubMed         Abstract available
    
    
12. YAMASAKI T, Yamanegi K, Ota H, Fujimoto D, et al
    Treatment-specific Association of H&E-based Stromal Tumor-infiltrating Lymphocytes With Survival in Pleural Mesothelioma Treated With Ipilimumab/Nivolumab or Chemotherapy.
    Anticancer Res. 2026;46:6193-6202.
    PubMed         Abstract available
    
    
13. TANIMURA T, Shiohara M, Ueno A, Kishimoto K, et al
    Integration of TRM-Cell Infiltration and PD-L1 Expression Improves Prognostic Stratification After Resection of NSCLC.
    Anticancer Res. 2026;46:6307-6318.
    PubMed         Abstract available
    
    
14. LIM JH, Jang JH, Lee J, Kim HJ, et al
    Positive Impact of Hypertension in Patients with Early-stage Lung Cancer Treated With Stereotactic Body Radiotherapy.
    Anticancer Res. 2026;46:6265-6273.
    PubMed         Abstract available
    
    

    
    BMC Cancer

15. XU R, Luo Z, Chen H, Ren N, et al
    Examined lymph node count as an independent predictive biomarker for adjuvant systemic therapy efficacy in stage IB lung adenocarcinoma.
    BMC Cancer. 2026;26:1326.
    PubMed         Abstract available
    
    
16. YAMAGUCHI H, Hisa M, Enta A, Maruya Y, et al
    Tertiary lymphoid structures in the tumor immune microenvironment of EGFR mutation-positive lung cancer are associated with prognosis: a retrospective review.
    BMC Cancer. 2026;26:1313.
    PubMed         Abstract available
    
    
17. SHEN L, Gao Y, Song Z, Wang Q, et al
    Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation.
    BMC Cancer. 2026;26:1327.
    PubMed         Abstract available
    
    
18. YAMASAKI H, Nakajima K, Ujiie H, Chiba R, et al
    CD44-targeted near-infrared photoimmunotherapy shows potent anti-tumor effects in an orthotopic lung cancer model.
    BMC Cancer. 2026;26:1329.
    PubMed         Abstract available
    
    
19. REHMAN N, Zabor EC, Dhakal A, Adcock B, et al
    Trends in treatment and survival of stage IV non-squamous NSCLC from 2010 to 2022.
    BMC Cancer. 2026;26:1312.
    PubMed         Abstract available
    
    
20. YAO D, Zhu XR, Guo JD, Song XY, et al
    Prognostic stratification by the ESTRO/EORTC oligometastatic classification and simplified binary approaches in lung cancer patients treated with stereotactic ablative radiotherapy.
    BMC Cancer. 2026;26:1293.
    PubMed         Abstract available
    
    
21. PANNIER P, Lebsir A, Ogor V, Calvet E, et al
    XPR1, key regulator of phosphate homeostasis and potential drug target for ovarian and lung cancer.
    BMC Cancer. 2026;26:1296.
    PubMed         Abstract available
    
    
22. RUAN Y, Xue H, Long C, Cao W, et al
    Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1286.
    PubMed         Abstract available
    
    

    
    Cancer Lett

23. MENG X, Chen L, Yang Y, Lin BX, et al
    PRODH promotes osimertinib drug-tolerant persistence in EGFR-mutant NSCLC by activating mitochondrial transcription.
    Cancer Lett. 2026;661:218885.
    PubMed         Abstract available
    
    
24. ANFRAY C, Pensado-Lopez A, Castro F, Rosales Sanchez A, et al
    Systemic administration of poly(I:C) and resiquimod reprograms tumor-associated macrophages and prevents tumor progression and metastasis in murine cancer models.
    Cancer Lett. 2026;661:218893.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

25. SPIGEL DR, Lo Russo G, Cousin S, Garrido P, et al
    ENTREE Lung: An Open-label Platform Study Investigating the Safety and Pharmacokinetics of Belrestotug Combinations in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Oct 26. doi: 10.1158/1078-0432.CCR-25-4851.
    PubMed         Abstract available
    
    

    
    Eur Respir J

26. PORCEL JM
    Don't discard the supernatant: pleural fluid cfDNA for molecular profiling in lung cancer.
    Eur Respir J. 2026 Oct 29:2601861. doi: 10.1183/13993003.01861-2026.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

27. NADEEM A, Rizvi SMA, Basaria AAA, Jalal L, et al
    Temporal trends and socio-demographic disparities in COPD-lung cancer co-occurrence mortality in the United States: a 22 year analysis (1999-2020).
    J Cancer Res Clin Oncol. 2026;152:206.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

28. JABBOUR SK, Soter S, Eaton M, Galffy G, et al
    KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Oct 28:JCO2600404. doi: 10.1200/JCO-26-00404.
    PubMed         Abstract available
    
    
29. SHAVERDIAN N, Riely GJ
    Immunotherapy With Stereotactic Body Radiation Therapy in Early-Stage Non?Small Cell Lung Cancer: Matching Risk, Biology, and Timing.
    J Clin Oncol. 2026 Oct 28:JCO2601966. doi: 10.1200/JCO-26-01966.
    PubMed        
    
    
30. REUSS J, Ismaila N, Doroshow DB, Feldman J, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4.
    J Clin Oncol. 2026 Oct 29:101200JCO2602597. doi: 10.1200/JCO-26-02597.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

31. POST KE, Trotter CS, Munankarmi AM, Chang P, et al
    Subgroup variations in benefit from telehealth palliative care for advanced lung cancer.
    J Natl Cancer Inst. 2026 Oct 29:djag408. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

32. DEBERTIN JG, Ortiz BA, Wigle DA, Shen KR, et al
    The additive effect of high-risk tumor features on long-term survival and recurrence in pathologic stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2026;172:1296-1304.
    PubMed         Abstract available
    
    
33. YANG Z, Xiong DX, Yuan EY, Cho JM, et al
    Resection outcomes according to pathologic risk in
    J Thorac Cardiovasc Surg. 2026;172:1305-1313.
    PubMed         Abstract available
    
    
34. SEYOUM N, Eaton DB Jr, Brennan L, Rossetti NE, et al
    Outcomes After Curative-intent Resection of Synchronous Primary Non-small cell lung cancer (NSCLC): Two is Worse than One.
    J Thorac Cardiovasc Surg. 2026 Oct 28:S0022-5223(26)01399.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

35. PRIELIPP R, Albers-Leischner C, Sharapova Y, Arnold J, et al
    Brief report: Clinical and Functional Characterization of Rare Germline and Somatic EGFR Variants in Three Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2026 Oct 30:106222. doi: 10.1016/j.jtho.2026.106222.
    PubMed         Abstract available
    
    
36. BONSA M, Mengistu Z, Yip R, Avila RS, et al
    Development and Implementation of an Integrated Early Lung Cancer Detection Program in Ethiopia: A Scalable Framework for Resource-Constrained Settings.
    J Thorac Oncol. 2026 Oct 30:106220. doi: 10.1016/j.jtho.2026.106220.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

37. JI Y, Li Q, Chen L, Pang Q, et al
    Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial.
    JAMA Oncol. 2026 Oct 29. doi: 10.1001/jamaoncol.2026.3918.
    PubMed         Abstract available
    
    

    
    Lancet

38. HONG S, Zhou T, Hou X, Meng X, et al
    Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, ph
    Lancet. 2026 Oct 26:S0140-6736(26)02026-X. doi: 10.1016/S0140-6736(26)02026.
    PubMed         Abstract available
    
    
39. XU CR, Zhang Y, Lin G, Wang H, et al
    Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.
    Lancet. 2026 Oct 26:S0140-6736(26)01899-4. doi: 10.1016/S0140-6736(26)01899.
    PubMed         Abstract available
    
    
40. SAW SPL, Aldea M
    Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability?
    Lancet. 2026 Oct 26:S0140-6736(26)01951-3. doi: 10.1016/S0140-6736(26)01951.
    PubMed        
    
    

    
    Lung Cancer

41. BONORA S, Daw M, Tabolacci C, Cortellini A, et al
    From whole-exome sequencing to functional insight: Characterization of rare germline variants in lung cancer.
    Lung Cancer. 2026;222:109663.
    PubMed         Abstract available
    
    
42. DE ROSA C, Diaz CA, Morillas JM, Sanchez Cespedes M, et al
    Targeting MYC in small cell lung cancer: Bridging molecular subtypes and therapeutic vulnerability.
    Lung Cancer. 2026;222:109672.
    PubMed         Abstract available
    
    
43. TERANISHI S, Misumi Y, Ishihara T, Yamanaka Y, et al
    Efficacy and safety of primary granulocyte colony-stimulating factor prophylaxis in patients with small-cell lung cancer receiving first-line platinum-etoposide plus a programmed death-ligand 1 inhibitor: A multicenter retrospective observational stud
    Lung Cancer. 2026;222:109671.
    PubMed         Abstract available
    
    
44. KIMANI L, Hyde G, O'Dowd E, Johns C, et al
    Lung cancer associated with cystic airspaces (LCCA): A comprehensive literature review undertaken as part of the British thoracic oncology group (BTOG) work programme.
    Lung Cancer. 2026;222:109651.
    PubMed         Abstract available
    
    

    
    N Engl J Med

45. PEROL M, Yoshida T, Ahn MJ, Gay CM, et al
    Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.
    N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2609482.
    PubMed         Abstract available
    
    
46. CHOI SJ
    Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2026;395:10.
    PubMed        
    
    
47. YUE D, Mao L, Wang C
    Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2026;395:10.
    PubMed        
    
    

    
    Nat Med

48. RECK M, Nadal E, Gay CM, Girard N, et al
    Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.
    Nat Med. 2026 Oct 26. doi: 10.1038/s41591-026-04742.
    PubMed         Abstract available
    
    

    
    Oncogene

49. XU Y, Han X, Li J, Zhang S, et al
    A canonical role of SMAD4 in safeguarding 3D genome architecture to suppress lung tumorigenesis.
    Oncogene. 2026;45:4743-4757.
    PubMed         Abstract available
    
    
50. FREY WD, Gu J, Oh YT, Chen L, et al
    ACK1 inhibition suppresses topoisomerase IIalpha, causing DNA damage accumulation and cellular senescence in RAS mutant lung cancer cells.
    Oncogene. 2026 Oct 28. doi: 10.1038/s41388-026-04033.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum